Recommendations for using beta-blockers in patients with COPD or asthma
Dispel fears about using beta-blockers in patients with COPD or asthma...
Alerts still pop up when beta-blockers are used in patients with COPD or asthma, but these shouldn't always raise a red flag. Many of us were taught to avoid beta-blockers in these patients because of concerns about bronchoconstriction. But cardioSELECTIVE options (metoprolol [Seloken Zoc], bisoprolol [Concor], nebivolol [Nebilet], etc) don't cause more exacerbations or reduce airway function in COPD or asthma. And patients still respond to beta-agonists (salbutamol [Ventolin], salmeterol [Metrovent], etc). Plus, evidence continues to grow that beta-blockers in general may actually DECREASE exacerbations and improve survival in COPD patients, probably by treating coexisting CV disease.
- Don't be concerned if COPD or asthma patients get a SELECTIVE beta-blocker especially in cases where they improve outcomes, such as after a heart attack or for heart failure with reduced ejection fraction (HFrEF).
- Advise starting with a low dose and titrating up.
- Continue to lean away from NONselective agents (carvedilol, propranolol, etc) in COPD, there's not much evidence of safety.
- Recommend avoiding nonselective beta-blockers entirely in asthma. There's evidence bronchospasm or exacerbations can occur.
- Be aware that even beta-blocker eye drops can result in significant blood levels and pose similar concerns in COPD or asthma. One drop of timolol 0.5% in each eye has about the same effect as 10 mg orally.
- Consider betaxolol (Betoptic) if needed it's the only selective eye drop.
- And educate patients to keep their eyes closed for at least one minute after instilling. This may limit absorption through tear ducts.
References
- Nielsen AO, Pedersen L, Sode BF, Dahl M. β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease - A Danish Nationwide Study of 1·3 Million Individuals. EClinicalMedicine. 2019 Jan 29;7:21-26.
- Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010 May 24;170(10):880-7.
- Morales, D.R., Lipworth, et al. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Medicine, 15(1).